A citation-based method for searching scientific literature

Wenyu Yu, Emma J Chory, Amy K Wernimont, Wolfram Tempel, Alex Scopton, Alexander Federation, Jason J Marineau, Jun Qi, Dalia Barsyte-Lovejoy, Joanna Yi, Richard Marcellus, Roxana E Iacob, John R Engen, Carly Griffin, Ahmed Aman, Erno Wienholds, Fengling Li, Javier Pineda, Guillermina Estiu, Tatiana Shatseva, Taraneh Hajian, Rima Al-Awar, John E Dick, Masoud Vedadi, Peter J Brown, Cheryl H Arrowsmith, James E Bradner, Matthieu Schapira. Nat Commun 2012
Times Cited: 181







List of co-cited articles
1717 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor.
Scott R Daigle, Edward J Olhava, Carly A Therkelsen, Christina R Majer, Christopher J Sneeringer, Jeffrey Song, L Danielle Johnston, Margaret Porter Scott, Jesse J Smith, Yonghong Xiao,[...]. Cancer Cell 2011
629
68

Potent inhibition of DOT1L as treatment of MLL-fusion leukemia.
Scott R Daigle, Edward J Olhava, Carly A Therkelsen, Aravind Basavapathruni, Lei Jin, P Ann Boriack-Sjodin, Christina J Allain, Christine R Klaus, Alejandra Raimondi, Margaret Porter Scott,[...]. Blood 2013
443
65

MLL-rearranged leukemia is dependent on aberrant H3K79 methylation by DOT1L.
Kathrin M Bernt, Nan Zhu, Amit U Sinha, Sridhar Vempati, Joerg Faber, Andrei V Krivtsov, Zhaohui Feng, Natalie Punt, Amanda Daigle, Lars Bullinger,[...]. Cancer Cell 2011
576
36

hDOT1L links histone methylation to leukemogenesis.
Yuki Okada, Qin Feng, Yihui Lin, Qi Jiang, Yaqiang Li, Vernon M Coffield, Lishan Su, Guoliang Xu, Yi Zhang. Cell 2005
571
34

Methylation of H3-lysine 79 is mediated by a new family of HMTases without a SET domain.
Qin Feng, Hengbin Wang, Huck Hui Ng, Hediye Erdjument-Bromage, Paul Tempst, Kevin Struhl, Yi Zhang. Curr Biol 2002
550
28

MLL translocations, histone modifications and leukaemia stem-cell development.
Andrei V Krivtsov, Scott A Armstrong. Nat Rev Cancer 2007
775
25


EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations.
Michael T McCabe, Heidi M Ott, Gopinath Ganji, Susan Korenchuk, Christine Thompson, Glenn S Van Aller, Yan Liu, Alan P Graves, Anthony Della Pietra, Elsie Diaz,[...]. Nature 2012
24

Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L.
Aravind Basavapathruni, Lei Jin, Scott R Daigle, Christina R A Majer, Carly A Therkelsen, Tim J Wigle, Kevin W Kuntz, Richard Chesworth, Roy M Pollock, Margaret P Scott,[...]. Chem Biol Drug Des 2012
92
26

The diverse functions of Dot1 and H3K79 methylation.
Anh Tram Nguyen, Yi Zhang. Genes Dev 2011
355
23

Selective inhibitors of histone methyltransferase DOT1L: design, synthesis, and crystallographic studies.
Yuan Yao, Pinhong Chen, Jiasheng Diao, Gang Cheng, Lisheng Deng, Justin L Anglin, B V Venkataram Prasad, Yongcheng Song. J Am Chem Soc 2011
114
22

H3K79 methylation profiles define murine and human MLL-AF4 leukemias.
Andrei V Krivtsov, Zhaohui Feng, Madeleine E Lemieux, Joerg Faber, Sridhar Vempati, Amit U Sinha, Xiaobo Xia, Jonathan Jesneck, Adrian P Bracken, Lewis B Silverman,[...]. Cancer Cell 2008
385
21

A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells.
Sarah K Knutson, Tim J Wigle, Natalie M Warholic, Christopher J Sneeringer, Christina J Allain, Christine R Klaus, Joelle D Sacks, Alejandra Raimondi, Christina R Majer, Jeffrey Song,[...]. Nat Chem Biol 2012
536
20

DOT1L, the H3K79 methyltransferase, is required for MLL-AF9-mediated leukemogenesis.
Anh Tram Nguyen, Olena Taranova, Jin He, Yi Zhang. Blood 2011
174
20

DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.
Chun-Wei Chen, Richard P Koche, Amit U Sinha, Aniruddha J Deshpande, Nan Zhu, Rowena Eng, John G Doench, Haiming Xu, Scott H Chu, Jun Qi,[...]. Nat Med 2015
133
20

Requirement for Dot1l in murine postnatal hematopoiesis and leukemogenesis by MLL translocation.
Stephanie Y Jo, Eric M Granowicz, Ivan Maillard, Dafydd Thomas, Jay L Hess. Blood 2011
146
19

A role for the MLL fusion partner ENL in transcriptional elongation and chromatin modification.
Dorothee Mueller, Christian Bach, Deniz Zeisig, Maria-Paz Garcia-Cuellar, Sara Monroe, Arun Sreekumar, Rong Zhou, Alexey Nesvizhskii, Arul Chinnaiyan, Jay L Hess,[...]. Blood 2007
273
19

Pharmacologic inhibition of the Menin-MLL interaction blocks progression of MLL leukemia in vivo.
Dmitry Borkin, Shihan He, Hongzhi Miao, Katarzyna Kempinska, Jonathan Pollock, Jennifer Chase, Trupta Purohit, Bhavna Malik, Ting Zhao, Jingya Wang,[...]. Cancer Cell 2015
194
19

Discovery of Novel Dot1L Inhibitors through a Structure-Based Fragmentation Approach.
Chao Chen, Hugh Zhu, Frédéric Stauffer, Giorgio Caravatti, Susanne Vollmer, Rainer Machauer, Philipp Holzer, Henrik Möbitz, Clemens Scheufler, Martin Klumpp,[...]. ACS Med Chem Lett 2016
33
57

An orally bioavailable chemical probe of the Lysine Methyltransferases EZH2 and EZH1.
Kyle D Konze, Anqi Ma, Fengling Li, Dalia Barsyte-Lovejoy, Trevor Parton, Christopher J Macnevin, Feng Liu, Cen Gao, Xi-Ping Huang, Ekaterina Kuznetsova,[...]. ACS Chem Biol 2013
277
18

A chemical probe selectively inhibits G9a and GLP methyltransferase activity in cells.
Masoud Vedadi, Dalia Barsyte-Lovejoy, Feng Liu, Sylvie Rival-Gervier, Abdellah Allali-Hassani, Viviane Labrie, Tim J Wigle, Peter A Dimaggio, Gregory A Wasney, Alena Siarheyeva,[...]. Nat Chem Biol 2011
337
18

Synthesis and structure-activity relationship investigation of adenosine-containing inhibitors of histone methyltransferase DOT1L.
Justin L Anglin, Lisheng Deng, Yuan Yao, Guobin Cai, Zhen Liu, Hong Jiang, Gang Cheng, Pinhong Chen, Shuo Dong, Yongcheng Song. J Med Chem 2012
63
28

The DOT1L inhibitor pinometostat reduces H3K79 methylation and has modest clinical activity in adult acute leukemia.
Eytan M Stein, Guillermo Garcia-Manero, David A Rizzieri, Raoul Tibes, Jesus G Berdeja, Michael R Savona, Mojca Jongen-Lavrenic, Jessica K Altman, Blythe Thomson, Stephen J Blakemore,[...]. Blood 2018
169
18

Histone demethylation mediated by the nuclear amine oxidase homolog LSD1.
Yujiang Shi, Fei Lan, Caitlin Matson, Peter Mulligan, Johnathan R Whetstine, Philip A Cole, Robert A Casero, Yang Shi. Cell 2004
17

The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells.
William J Harris, Xu Huang, James T Lynch, Gary J Spencer, James R Hitchin, Yaoyong Li, Filippo Ciceri, Julian G Blaser, Brigit F Greystoke, Allan M Jordan,[...]. Cancer Cell 2012
383
17

DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells.
David J Steger, Martina I Lefterova, Lei Ying, Aaron J Stonestrom, Michael Schupp, David Zhuo, Adam L Vakoc, Ja-Eun Kim, Junjie Chen, Mitchell A Lazar,[...]. Mol Cell Biol 2008
310
17

Targeting MLL1 H3K4 methyltransferase activity in mixed-lineage leukemia.
Fang Cao, Elizabeth C Townsend, Hacer Karatas, Jing Xu, Li Li, Shirley Lee, Liu Liu, Yong Chen, Peter Ouillette, Jidong Zhu,[...]. Mol Cell 2014
188
17

Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia.
Mark A Dawson, Rab K Prinjha, Antje Dittmann, George Giotopoulos, Marcus Bantscheff, Wai-In Chan, Samuel C Robson, Chun-wa Chung, Carsten Hopf, Mikhail M Savitski,[...]. Nature 2011
16


Bromo-deaza-SAH: a potent and selective DOT1L inhibitor.
Wenyu Yu, David Smil, Fengling Li, Wolfram Tempel, Oleg Fedorov, Kong T Nguyen, Yuri Bolshan, Rima Al-Awar, Stefan Knapp, Cheryl H Arrowsmith,[...]. Bioorg Med Chem 2013
42
38

Linking H3K79 trimethylation to Wnt signaling through a novel Dot1-containing complex (DotCom).
Man Mohan, Hans-Martin Herz, Yoh-Hei Takahashi, Chengqi Lin, Ka Chun Lai, Ying Zhang, Michael P Washburn, Laurence Florens, Ali Shilatifard. Genes Dev 2010
201
15

A Potent, Selective, and Cell-Active Inhibitor of Human Type I Protein Arginine Methyltransferases.
Mohammad S Eram, Yudao Shen, Magdalena Szewczyk, Hong Wu, Guillermo Senisterra, Fengling Li, Kyle V Butler, H Ümit Kaniskan, Brandon A Speed, Carlo Dela Seña,[...]. ACS Chem Biol 2016
106
15

A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models.
Elayne Chan-Penebre, Kristy G Kuplast, Christina R Majer, P Ann Boriack-Sjodin, Tim J Wigle, L Danielle Johnston, Nathalie Rioux, Michael J Munchhof, Lei Jin, Suzanne L Jacques,[...]. Nat Chem Biol 2015
268
15

Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.
Aniruddha J Deshpande, Liying Chen, Maurizio Fazio, Amit U Sinha, Kathrin M Bernt, Deepti Banka, Stuart Dias, Jenny Chang, Edward J Olhava, Scott R Daigle,[...]. Blood 2013
115
15

DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells.
Christine R Klaus, Dorothy Iwanowicz, Danielle Johnston, Carly A Campbell, Jesse J Smith, Mikel P Moyer, Robert A Copeland, Edward J Olhava, Margaret Porter Scott, Roy M Pollock,[...]. J Pharmacol Exp Ther 2014
75
18

The Polycomb complex PRC2 and its mark in life.
Raphaël Margueron, Danny Reinberg. Nature 2011
14

Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Ryan D Morin, Nathalie A Johnson, Tesa M Severson, Andrew J Mungall, Jianghong An, Rodrigo Goya, Jessica E Paul, Merrill Boyle, Bruce W Woolcock, Florian Kuchenbauer,[...]. Nat Genet 2010
14


Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.
L Chen, A J Deshpande, D Banka, K M Bernt, S Dias, C Buske, E J Olhava, S R Daigle, V M Richon, R M Pollock,[...]. Leukemia 2013
97
14

AF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.
Aniruddha J Deshpande, Anagha Deshpande, Amit U Sinha, Liying Chen, Jenny Chang, Ali Cihan, Maurizio Fazio, Chun-Wei Chen, Nan Zhu, Richard Koche,[...]. Cancer Cell 2014
105
14

The emerging roles of DOT1L in leukemia and normal development.
C M McLean, I D Karemaker, F van Leeuwen. Leukemia 2014
76
18

RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Johannes Zuber, Junwei Shi, Eric Wang, Amy R Rappaport, Harald Herrmann, Edward A Sison, Daniel Magoon, Jun Qi, Katharina Blatt, Mark Wunderlich,[...]. Nature 2011
14

MLL-AF9-induced leukemogenesis requires coexpression of the wild-type Mll allele.
Austin T Thiel, Peter Blessington, Tao Zou, Danielle Feather, Xinjiang Wu, Jizhou Yan, Hui Zhang, Zuguo Liu, Patricia Ernst, Gary A Koretzky,[...]. Cancer Cell 2010
174
14

Optimization of a Fragment-Based Screening Hit toward Potent DOT1L Inhibitors Interacting in an Induced Binding Pocket.
Clemens Scheufler, Henrik Möbitz, Christoph Gaul, Christian Ragot, Céline Be, César Fernández, Kim S Beyer, Ralph Tiedt, Frédéric Stauffer. ACS Med Chem Lett 2016
24
58

Protein methyltransferases as a target class for drug discovery.
Robert A Copeland, Michael E Solomon, Victoria M Richon. Nat Rev Drug Discov 2009
327
13

Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in EZH2-mutant non-Hodgkin lymphoma.
Sarah K Knutson, Satoshi Kawano, Yukinori Minoshima, Natalie M Warholic, Kuan-Chun Huang, Yonghong Xiao, Tadashi Kadowaki, Mai Uesugi, Galina Kuznetsov, Namita Kumar,[...]. Mol Cancer Ther 2014
328
13

LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription.
Eric Metzger, Melanie Wissmann, Na Yin, Judith M Müller, Robert Schneider, Antoine H F M Peters, Thomas Günther, Reinhard Buettner, Roland Schüle. Nature 2005
13

Misguided transcriptional elongation causes mixed lineage leukemia.
Dorothee Mueller, María-Paz García-Cuéllar, Christian Bach, Sebastian Buhl, Emanuel Maethner, Robert K Slany. PLoS Biol 2009
145
13

Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor.
Aravind Basavapathruni, Edward J Olhava, Scott R Daigle, Carly A Therkelsen, Lei Jin, P Ann Boriack-Sjodin, Christina J Allain, Christine R Klaus, Alejandra Raimondi, Margaret Porter Scott,[...]. Biopharm Drug Dispos 2014
53
24

Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation.
Wei Qi, HoMan Chan, Lin Teng, Ling Li, Shannon Chuai, Ruipeng Zhang, Jue Zeng, Min Li, Hong Fan, Ying Lin,[...]. Proc Natl Acad Sci U S A 2012
389
13


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.